Non-small Cell Lung Cancer Clinical Trial
Official title:
A Phase II Study of Radiotherapy and ZADAXIN's® (Thymalfasin) Induced Abscopal Effect in Patients With Heavily Pretreated, Metastatic Non-small Cell Lung Cancer.
Patients with Non-small cell lung cancer that had metastatic lesions after been treated with
definitive surgery or chemoradiotherapy are being asked to participate in this study.
1. To observe immunity-mediated tumor response outside the radiation field (abscopal
effect) after chemoradiotherapy of a metastatic site in metastatic Non-small cell lung
cancer patients.
2. To induce the efficacy (effectiveness) of a new combination of therapy,
chemoradiotherapy and thymalfasin for heavily pretreated, metastatic Non-small cell lung
cancer patients;
3. To explore the role of PET/CT scanning to assess tumor response/abscopal effect.
This study will help find out what abscopal effects (good or bad) the combination of
radiotherapy and thymalfasin has on metastatic Non-small cell lung cancer.
1. To observe immunity-mediated tumor response outside the radiation field (abscopal
effect) after chemoradiotherapy of a metastatic site in metastatic Non-small cell lung
cancer patients.
2. To induce the efficacy (effectiveness) of a new combination of therapy,
chemoradiotherapy and thymalfasin for heavily pretreated, metastatic Non-small cell lung
cancer patients;
3. To explore the role of PET/CT scanning to assess tumor response/abscopal effect.
Eligible are patients with metastatic Non-small cell lung cancer who have achieved stable
disease or have disease progression after systemic therapy (surgery or definitive
chemoradiotherapy) and have at least three separate measurable sites of metastatic lesions.
Extent of metastatic disease is recorded both at CT and PET/CT scanning. Radiation is given
during combined therapy to one of the lesions, 35Gy in 10 fractions over a two week interval,
conformally to maximally spare normal tissue or organ. Thymalfasin treatment is given twice a
week with an interval of 3-4 days each week. At day 22 radiation is re-started and the same
radiation dose is delivered to a second metastatic site, again with thymalfasin. Abscopal
response is evaluated by assessing clinical and PET/CT response in the non-irradiated
measurable metastatic sites. A Phase II clinical trial based on an optimum two-stage Phase II
Simon design is used to conduct this pilot study. Ten patients will be treated in Stage one;
if there are no abscopal responses, the trial will be terminated. If there are one or more
abscopal responses in Stage One, the trial will proceed to enroll an additional 19 patients.
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Terminated |
NCT03087448 -
Ceritinib + Trametinib in Patients With Advanced ALK-Positive Non-Small Cell Lung Cancer (NSCLC)
|
Phase 1 | |
| Recruiting |
NCT05042375 -
A Trial of Camrelizumab Combined With Famitinib Malate in Treatment Naïve Subjects With PD-L1-Positive Recurrent or Metastatic Non-Small Cell Lung Cancer
|
Phase 3 | |
| Completed |
NCT02526017 -
Study of Cabiralizumab in Combination With Nivolumab in Patients With Selected Advanced Cancers
|
Phase 1 | |
| Enrolling by invitation |
NCT00068003 -
Harvesting Cells for Experimental Cancer Treatments
|
||
| Terminated |
NCT05414123 -
A Therapy Treatment Response Trial in Patients With Leptomeningeal Metastases ((LM) Using CNSide
|
||
| Recruiting |
NCT05059444 -
ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation
|
||
| Recruiting |
NCT05919537 -
Study of an Anti-HER3 Antibody, HMBD-001, With or Without Chemotherapy in Patients With Solid Tumors Harboring an NRG1 Fusion or HER3 Mutation
|
Phase 1 | |
| Recruiting |
NCT05009836 -
Clinical Study on Savolitinib + Osimertinib in Treatment of EGFRm+/MET+ Locally Advanced or Metastatic NSCLC
|
Phase 3 | |
| Recruiting |
NCT03412877 -
Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer
|
Phase 2 | |
| Active, not recruiting |
NCT03170960 -
Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors
|
Phase 1/Phase 2 | |
| Completed |
NCT03219970 -
Efficacy and Safety of Osimertinib for HK Chinese With Metastatic T790M Mutated NSCLC-real World Setting.
|
||
| Recruiting |
NCT05949619 -
A Study of BL-M02D1 in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer or Other Solid Tumors
|
Phase 1/Phase 2 | |
| Recruiting |
NCT04054531 -
Study of KN046 With Chemotherapy in First Line Advanced NSCLC
|
Phase 2 | |
| Withdrawn |
NCT03519958 -
Epidermal Growth Factor Receptor (EGFR) T790M Mutation Testing Practices in Hong Kong
|
||
| Completed |
NCT03384511 -
The Use of 18F-ALF-NOTA-PRGD2 PET/CT Scan to Predict the Efficacy and Adverse Events of Apatinib in Malignancies.
|
Phase 4 | |
| Terminated |
NCT02580708 -
Phase 1/2 Study of the Safety and Efficacy of Rociletinib in Combination With Trametinib in Patients With mEGFR-positive Advanced or Metastatic Non-small Cell Lung Cancer
|
Phase 1/Phase 2 | |
| Completed |
NCT01871805 -
A Study of Alectinib (CH5424802/RO5424802) in Participants With Anaplastic Lymphoma Kinase (ALK)-Rearranged Non-Small Cell Lung Cancer (NSCLC)
|
Phase 1/Phase 2 | |
| Terminated |
NCT04042480 -
A Study of SGN-CD228A in Advanced Solid Tumors
|
Phase 1 | |
| Recruiting |
NCT05919641 -
LIVELUNG - Impact of CGA in Patients Diagnosed With Localized NSCLC Treated With SBRT
|
||
| Completed |
NCT03656705 -
CCCR-NK92 Cells Immunotherapy for Non-small Cell Lung Carcinoma
|
Phase 1 |